PD-L1 expression and survival among patients with advanced non–small cell lung cancer treated with chemotherapy

Translational Oncology

Volumn 9, Issue 1, 2016, Pages 64-69

  Sorensen, Steffen Filskov ^a   Zhou, Wei ^b   Dolled Filhart, Marisa ^b   Georgsen, Jeanette Baehr ^a   Wang, Zhen ^c   Emancipator, Kenneth ^b   Wu, Dianna ^b   Busch Sørensen, Michael ^d   Meldgaard, Peter ^a   Hager, Henrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MSD China   (China)

^d MSD Denmark   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; NAVELBINE; PEMBROLIZUMAB; PLATINUM; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; SQUAMOUS CELL LUNG CARCINOMA; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

EID: 84974691152     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2016.01.003     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z, and Jemal A (2014). Cancer statistics, 2014. CA Cancer J Clin 64(1), 9–29 http://dx.doi.org/10.3322/caac.21208.
2. Chan BA and Hughes BG (2015). Targeted therapy for non–small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 4(1), 36–54 http://dx.doi.org/10.3978/j.issn.2218-6751.2014.05.01.
3. Garon EB, Rizvi NA, Leighl N, Balmanoukian AS, Eder JP, and Patnaik A, et al (2015). Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 372(21), 2018–2028 http://dx.doi.org/10.1056/NEJMoa1501824.
4. Gettinger SN, Shepherd FA, Antonia SJ, Brahmer JR, Man Chow LQ, and Juergens RA, et al (2014). First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol 32(5 Suppl.) [abstract 8024].
5. Soria JC, Cruz C, Bahleda R, Delord J, Horn L, and Herbst R, et al (2013). Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PD-L1). Presented at the European Cancer Congress (ECC) 2013; September 27–October 3, 2013; Amsterdam, The Netherlands; 2013 [abstract 3408].
6. Mahoney KM and Atkins MB (2014). Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) 28(Suppl. 3), 39–48.
7. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, and Krook J, et al (2002). Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med 346(2), 92–98.
8. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, and Paesmans M, et al (2007). Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non–small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99(11), 847–857.
9. Coate LE, John T, Tsao MS, and Shepherd FA (2009). Molecular predictive and prognostic markers in non–small-cell lung cancer. Lancet Oncol 10(10), 1001–1010. http://dx.doi.org/10.1016/S1470-2045(09)70155-X.
10. Philips GK and Atkins M (2015). Therapeutic uses of anti–PD-1 and anti–PD-L1 antibodies. Int Immunol 27(1), 39–46. http://dx.doi.org/10.1093/intimm/dxu095.
11. Domingues D, Turner A, Silva MD, Marques DS, Mellidez JC, and Wannesson L, et al (2014). Immunotherapy and lung cancer: current developments and novel targeted therapies. Immunotherapy 6(11), 1221–1235. http://dx.doi.org/10.2217/imt.14.82.
12. Casaluce F, Sgambato A, Sacco PC, Palazzolo G, Maione P, and Rossi A, et al (2014). Emerging drugs targeting PD-1 and PD-L1: reality or hope? Expert Opin Emerg Drugs 19(4), 557–569. http://dx.doi.org/10.1517/14728214.2014.964682.
13. Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, and Gillanders WE (2013). The presence of programmed death 1 (PD-1)–positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 139(3), 667–676. http://dx.doi.org/10.1007/s10549-013-2581-3.
14. Zhang Y, Wang L, Li Y, Pan Y, Wang R, and Hu H, et al (2014). Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Oncol Targets Ther 7, 567–573. http://dx.doi.org/10.2147/OTT.S59959.
15. Muenst S, Schaerli AR, Gao F, Daster S, Trella E, and Droeser RA, et al (2014). Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 146(1), 15–24. http://dx.doi.org/10.1007/s10549-014-2988-5.
16. Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, and Tokito T, et al (2015). Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol 10(3), 426–430. http://dx.doi.org/10.1097/JTO.0000000000000414.
17. Massi D, Brusa D, Merelli B, Ciano M, Audrito V, and Serra S, et al (2014). PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol 25(12), 2433–2442. http://dx.doi.org/10.1093/annonc/mdu452.
18. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, and Webster WS, et al (2006). Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66(7), 3381–3385.
19. Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, and Albiges L, et al (2014). PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 25(11), 2178–2184. http://dx.doi.org/10.1093/annonc/mdu445.
20. Mu CY, Huang JA, Chen Y, Chen C, and Zhang XG (2011). High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 28(3), 682–688. http://dx.doi.org/10.1007/s12032-010-9515-2.
21. Chen YB, Mu CY, and Huang JA (2012).Clinical significance of programmed death-1 ligand-1 expression in patients with non–small cell lung cancer: a 5-year-follow-up study. Tumori 98(6), 751–755. http://dx.doi.org/10.1700/1217.13499.
22. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, and Sznol M, et al (2014). Programmed death ligand-1 expression in non–small cell lung cancer. Lab Invest 94(1), 107–116. http://dx.doi.org/10.1038/labinvest.2013.130.
23. Yang CY, Lin MW, Chang YL, Wu CT, and Yang PC (2014). Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 50(7), 1361–1369. http://dx.doi.org/10.1016/j.ejca.2014.01.018.
24. Zhang Y, Kang S, Shen J, He J, Jiang L, and Wang W, et al (2015). Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore) 94(6), e515. http://dx.doi.org/10.1097/MD.0000000000000515.
25. Zhou ZJ, Zhan P, and Song Y (2015). PD-L1 over-expression and survival in patients with non–small cell lung cancer: a meta-analysis. Transl Lung Cancer Res 4(2), 203–208. http://dx.doi.org/10.3978/j.issn.2218-6751.2015.03.02.
26. Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, and Lu ZY, et al (2015). The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol. http://dx.doi.org/10.1016/-j.ejso.2015.01.020 [Epub Jan 31].
27. Sun J-M, Zhou W, Choi Y-L, Choi S-J, Kim SE, and Wang Z, et al (2014). PD-L1 expression and survival in patients with non–small cell lung cancer (NSCLC) in Korea. J Clin Oncol 32(5 Suppl.) [abstract 8066].
28. Garon EB, Leighl NB, Rizvi NA, Blumenschein GR, Balmanoukian AS, and Eder JP, et al (2014). Safety and clinical activity of MK-3475 in previously treated patients (pts) with non–small cell lung cancer (NSCLC). J Clin Oncol 32(5 Suppl.) [abstract 8020].
29. D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, and Landi L, et al (2015). PD-1 and PD-L1 expression in molecularly selected non–small-cell lung cancer patients. Br J Cancer 112(1), 95–102. http://dx.doi.org/10.1038/bjc.2014.555.
30. Patel SP and Kurzrock R (2015). PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14(4), 847–856.